214 related articles for article (PubMed ID: 26382894)
1. Long-Term Outcomes of High-Risk Keratoplasty in Patients Receiving Systemic Immunosuppression.
Chow SP; Cook SD; Tole DM
Cornea; 2015 Nov; 34(11):1395-9. PubMed ID: 26382894
[TBL] [Abstract][Full Text] [Related]
2. Systemic immunosuppression with mycophenolate mofetil to prevent corneal graft rejection after high-risk penetrating keratoplasty: a 2-year follow-up study.
Szaflik JP; Major J; Izdebska J; Lao M; Szaflik J
Graefes Arch Clin Exp Ophthalmol; 2016 Feb; 254(2):307-14. PubMed ID: 26553197
[TBL] [Abstract][Full Text] [Related]
3. Sirolimus and mycophenolate as combination prophylaxis in corneal transplant recipients at high rejection risk.
Chatel MA; Larkin DF
Am J Ophthalmol; 2010 Aug; 150(2):179-84. PubMed ID: 20570235
[TBL] [Abstract][Full Text] [Related]
4. Mycophenolate mofetil (MMF) following penetrating high-risk keratoplasty: long-term results of a prospective, randomised, multicentre study.
Birnbaum F; Mayweg S; Reis A; Böhringer D; Seitz B; Engelmann K; Messmer EM; Reinhard T
Eye (Lond); 2009 Nov; 23(11):2063-70. PubMed ID: 19151659
[TBL] [Abstract][Full Text] [Related]
5. Systemic mycophenolate mofetil in comparison with systemic cyclosporin A in high-risk keratoplasty patients: 3 years' results of a randomized prospective clinical trial.
Reinhard T; Reis A; Böhringer D; Malinowski M; Voiculescu A; Heering P; Godehardt E; Sunmacher R
Graefes Arch Clin Exp Ophthalmol; 2001 Jun; 239(5):367-72. PubMed ID: 11482341
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of postoperative immunosuppression after keratoplasty in herpetic keratitis.
Maier AK; Ozlügedik S; Rottler J; Heussen FM; Klamann MK; Huber KK; Joussen AM; Winterhalter S
Cornea; 2011 Dec; 30(12):1398-405. PubMed ID: 21996945
[TBL] [Abstract][Full Text] [Related]
7. Indications, outcomes, and risk factors for failure in tectonic keratoplasty.
Ang M; Mehta JS; Sng CC; Htoon HM; Tan DT
Ophthalmology; 2012 Jul; 119(7):1311-9. PubMed ID: 22541633
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of systemic tacrolimus in high-risk penetrating keratoplasty after graft failure with systemic cyclosporine.
Yamazoe K; Yamazoe K; Yamaguchi T; Omoto M; Shimazaki J
Cornea; 2014 Nov; 33(11):1157-63. PubMed ID: 25255133
[TBL] [Abstract][Full Text] [Related]
9. [Postoperative therapy after penetrating keratoplasty in herpes simplex keratitis].
Süveges I; Füst Á; Imre L
Orv Hetil; 2013 Dec; 154(52):2065-70. PubMed ID: 24374582
[TBL] [Abstract][Full Text] [Related]
10. Tacrolimus immunosuppression in high-risk corneal grafts.
Joseph A; Raj D; Shanmuganathan V; Powell RJ; Dua HS
Br J Ophthalmol; 2007 Jan; 91(1):51-5. PubMed ID: 16956911
[TBL] [Abstract][Full Text] [Related]
11. Large-diameter penetrating keratoplasty: indications and outcomes.
Skeens HM; Holland EJ
Cornea; 2010 Mar; 29(3):296-301. PubMed ID: 20118782
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus (FK506) in the management of high-risk corneal and limbal grafts.
Sloper CM; Powell RJ; Dua HS
Ophthalmology; 2001 Oct; 108(10):1838-44. PubMed ID: 11581059
[TBL] [Abstract][Full Text] [Related]
13. Preoperative introduction and maintenance immunosuppression therapy of oral-only tacrolimus, mycophenolate mofetil and steroids reduce acute rejection episodes after lung transplantation.
Bittner HB; Barten MJ; Binner C; Lehmann S; Garbade J; Hammerschmidt S; Wirtz H; Mohr FW
Eur J Cardiothorac Surg; 2010 Sep; 38(3):268-76. PubMed ID: 20304665
[TBL] [Abstract][Full Text] [Related]
14. Descemet stripping automated endothelial keratoplasty after failed penetrating keratoplasty: survival, rejection risk, and visual outcome.
Mitry D; Bhogal M; Patel AK; Lee BS; Chai SM; Price MO; Price FW; Jun AS; Aldave AJ; Mehta JS; Busin M; Allan BD
JAMA Ophthalmol; 2014 Jun; 132(6):742-9. PubMed ID: 24763830
[TBL] [Abstract][Full Text] [Related]
15. Three-year observational follow-up of a multicenter, randomized trial on tacrolimus-based therapy with withdrawal of steroids or mycophenolate mofetil after renal transplant.
Pascual J; van Hooff JP; Salmela K; Lang P; Rigotti P; Budde K
Transplantation; 2006 Jul; 82(1):55-61. PubMed ID: 16861942
[TBL] [Abstract][Full Text] [Related]
16. Systemic immunosuppression in ocular surface stem cell transplantation: results of a 10-year experience.
Holland EJ; Mogilishetty G; Skeens HM; Hair DB; Neff KD; Biber JM; Chan CC
Cornea; 2012 Jun; 31(6):655-61. PubMed ID: 22333664
[TBL] [Abstract][Full Text] [Related]
17. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
[TBL] [Abstract][Full Text] [Related]
18. Long-term comparison of full-bed deep lamellar keratoplasty with penetrating keratoplasty in treating corneal leucoma caused by herpes simplex keratitis.
Wu SQ; Zhou P; Zhang B; Qiu WY; Yao YF
Am J Ophthalmol; 2012 Feb; 153(2):291-299.e2. PubMed ID: 21996306
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of corneal graft survival in infants and children with peters anomaly.
Yang LL; Lambert SR; Lynn MJ; Stulting RD
Ophthalmology; 1999 Apr; 106(4):833-48. PubMed ID: 10201611
[TBL] [Abstract][Full Text] [Related]
20. The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model.
Birnbaum F; Schwartzkopff J; Scholz C; Reis A; Reinhard T
Eye (Lond); 2007 Dec; 21(12):1516-23. PubMed ID: 17401326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
